Urethral carcinoma in situ: recognition and management

Berjeaut, Ricardo Haidar; Persaud, Maliza; Sopko, Nikolai A.; Burnett, Arthur L.

doi:10.1007/s11255-017-1512-3

Cited by 6 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Insufficient information is available about sex-related disparities associated with clinicopathological features and survival of patients with PUC 4. Therefore, there is controversy about the contribution of sex differences to survival and prognosis 5–7. The purpose of the present study was to address this question.…”

Section: Introductionmentioning

confidence: 95%

Sex-related differences in clinicopathological features and survival of patients with primary urethral carcinoma: a population-based study

Wei¹,

Wu²,

Xu³

et al. 2017

OTT

View full text Add to dashboard Cite

PurposeTo analyze the Surveillance, Epidemiology, and End Results (SEER) database to determine the effects of sex and prognostic factors on the survival of patients with primary urethral carcinoma (PUC).Materials and methodsWe selected 453 patients diagnosed with PUC from 2004 to 2013 from the SEER database. Statistical analysis was used to identify sex-specific differences associated with tumor characteristics and cancer-specific survival (CSS) and overall survival (OS).ResultsCompared with men, there was a higher proportion of black women, more negative lymph-node status, higher American Joint Committee on Cancer (AJCC) stage, more advanced T3 stage, more with adenocarcinoma (Ac), and fewer with squamous cell carcinoma (SCC) or transitional cell carcinoma (TCC). Among women, black race and M1 stage were associated with shorter CSS and OS, respectively. In addition, surgery was associated with longer OS in women. Among men, AJCC III and IV and M1 stages were associated with shorter CSS and OS. In addition, age >75 years associated with shorter OS in men.ConclusionBlack race was associated with shorter OS and CSS of women, and surgery was associated with longer OS of women. Among men, AJCC stage III and IV were associated with shorter OS and CSS. Age >75 years was associated with shorter OS in men only. Women with Ac experienced poor CSS compared with men. Men with TCC experienced worse CSS compared with those with Ac or SCC.

show abstract

Section: Introductionmentioning

confidence: 95%

Sex-related differences in clinicopathological features and survival of patients with primary urethral carcinoma: a population-based study

Wei¹,

Wu²,

Xu³

et al. 2017

OTT

View full text Add to dashboard Cite

show abstract

“…The majority of patients with this condition have no evident symptoms in the early stages and are in the advanced stages when diagnosed, with considerable invasiveness and a poor prognosis. [1][2][3][4][5][6] The incidence of primary female urethral carcinoma is 1.5/100,000 people in the United States, and it rises with age. The incidence of primary female urethral carcinoma is 0.6/ 100,000 people in Europe.…”

Section: Introductionmentioning

confidence: 99%

Chemotherapy combined with immunotherapy in primary female urethral squamous cell carcinoma: a case report

et al. 2022

View full text Add to dashboard Cite

Primary female urethral carcinomas are uncommon and have a low morbidity rate. Most of these patients have advanced illness with high invasion and a poor prognosis. There is no standard treatment, and multimodal therapy is recommended. The use of radiotherapy and chemotherapy were mostly reported in previous studies on advanced female urethral squamous cell carcinoma. We report that chemotherapy combined with a programmed death-1 (PD-1) inhibitor was effective in treating metastatic female urethral squamous cell carcinoma. During four cycles, we used systemic chemotherapy of albumin-paclitaxel + carboplatin in combination with a PD-1 inhibitor (toripalimab 240 mg) every 3 weeks, and a complete response was achieved. We performed a genetic test on the patient who had a tumor mutation burden of 5.7 mutations/Mb, tumor proportion score of 20%, and combined positive score of 20% (22C3). No recurrence or distant metastasis was found after 20 months of follow-up. In conclusion, in patients with positive PD-1 ligand 1 expression in primary female urethral squamous cell carcinoma, chemotherapy combined with PD-1 inhibitors may be effective. Larger sample studies are required to determine PD-1 ligand 1 expression and the curative effect of PD-1 inhibitors, as well as their effect on survival.

show abstract

“…The European Association of Urology (EAU) defines a tumor with its very first lesion located in the urethra as primary urethral cancer (PUC) [1]. It is a very aggressive malignant tumor with high invasiveness both in men and women [2, 3], which accounts for less than 1% of all malignant tumors and 5% of the malignant tumors of the urinary system [4]. However, with social development and the destruction of the environment, the prevalence of the disease has shown an upward tendency.…”

Section: Introductionmentioning

confidence: 99%

Advanced primary urethral cancer: a case report

et al. 2019

View full text Add to dashboard Cite

BackgroundPrimary urethral cancer is exceedingly rare, resulting in a limitation in clinicians’ experience, and an accurate diagnosis is often delayed due to the non-specific clinical presentation. Here, we present this case report to show the treatment of a patient with primary urethral cancer. Our patient was diagnosed as having primary urethral cancer in the First Clinical Hospital of Yichang by cystoscopy and biopsy. Due to her age, poor physical tolerance, and economic condition, she refused radical operation. Since there is no definite guideline for the treatment process of primary urethral cancer in clinics, operation methods and postoperative adjuvant treatments vary in different hospitals, leading to diverse prognostic effects.Case presentationAn 88-year-old Asian woman had difficulty in urinating for more than 6 months and the syndrome was aggravated for 1 month. She chose a relatively conservative treatment plan: primary tumor resection combined with bladder perfusion chemotherapy. Postoperative pathology revealed “urethra” high-grade urothelial carcinoma (sarcoma-like variants) with extensive necrosis. After treatment with intravesical chemotherapeutic drug (hydroxycamptothecin 40 mg), she was eventually released from our hospital in a stable condition. Postoperation follow-up was performed to observe to what extent this conservative treatment plan improved the quality of life and overall survival time of our patient.ConclusionsShe needed radical resection according to the actual situation. However, her age restricted her tolerance to general anesthesia; relatively conservative treatment options are available to ensure a high quality of life. The treatment of primary tumor resection combined with bladder perfusion chemotherapy is feasible. This case highlights the importance of the dissemination of new cases and optimizing primary urethral cancer diagnosis to obtain an effective treatment.

show abstract

Urethral carcinoma in situ: recognition and management

Abstract: This is the largest series of urethral CIS, a disease with potentially serious consequences. A high index of suspicion should be maintained when evaluating and managing these patients.

Cited by 6 publications

References 20 publications

Sex-related differences in clinicopathological features and survival of patients with primary urethral carcinoma: a population-based study

Sex-related differences in clinicopathological features and survival of patients with primary urethral carcinoma: a population-based study

Chemotherapy combined with immunotherapy in primary female urethral squamous cell carcinoma: a case report

Advanced primary urethral cancer: a case report

Contact Info

Product

Resources

About